You are here

Naldemedine Shows Promise in Treatment of Opioid-Induced Constipation

Drug meets primary and secondary endpoints in phase III study

A phase III trial of once-daily naldemedine (Shionogi Inc.), an investigational peripherally acting mu opioid receptor antagonist (PAMORA), has met its primary and secondary endpoints in adult patients with chronic noncancer pain and opioid-induced constipation (OIC). This is the third phase III study in which naldemedine reached its primary and key secondary goals.

The COMPOSE II trial was a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. It was designed to evaluate the efficacy and safety of naldemedine compared with placebo in 553 patients who had experienced chronic noncancer pain accompanied by OIC during at least 12 weeks of opioid therapy.

The study results showed that a 0.2-mg tablet of naldemedine administered once daily significantly improved the frequency of spontaneous bowel movements (SBMs) compared with placebo during 12 weeks of treatment. The most common adverse events associated with naldemedine were gastrointestinal disorders.

OIC is characterized by any of the following symptoms: reduced bowel movement frequency; the development or worsening of straining to pass bowel movements; a sense of incomplete rectal evacuation; or harder stool consistency. It has been estimated that 40% to 50% of patients receiving chronic opioid therapy –– approximately 11 million Americans –– experience OIC, with fewer than half reporting satisfactory results with laxatives.

Source: Shionogi Inc.; August 3, 2015.


Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Data show PTC Therapeutics drug preserves lung function
U.S. maintains measles elimination status as NY outbreak ebbs
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive